HD-CARE supports the UCI Thompson Lab, which is located in the UCI Sue and Bill Gross Stem Cell Research Center (SCRC). The SCRC thanked us for making 2023 an incredible…
Huntington Study Group® and Roche Collaborate on Generation HD2 Study
Exciting new collaboration between the Huntington's Study Group (HSG) and Roche therapeutics. HSG will advise Roche on recruitment and enrollment of the needs of GENERATION HD2. This work will collectively…
SAGE Therapeutics announces FDA approved drug for HD cognitive therapy
SAGE therapeutics is a biopharmaceutical company with the mission of improving brain health. On 11/13/23, SAGE announcted that the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD)…
Youthful competitors: young brain cells oust the old
A recent publication that has garnered a lot of press looked at the effects of replacing cells in the brains of mice that model HD - with surprising findings. The…
New FDA Approved Drug for Chorea
The Huntington Study Group (HSG) shared that the Phase 3 KINECT-HD study resulted in FDA approval of valbenazine for treatment of chorea in Huntington's disease (HD). As a vesicular monoamine…
Join us for Sounds of the Bayou!
Register today! HD-Care invites you to our summer fundraiser on Saturday September 30, 2023 1-4pm at Campus Jax. Live music and "Live Ask" opportunity to support HD research and patient…
What is Huntington’s Disease? Find out in this Podcast!
Dr. Leslie Thompson, professor of Psychiatry & Human Behavior, Neurobiology and Behavior, and Chemistry, discusses Huntington's Disease and possible treatment strategies on the UCI MIND podcast. Check out the full…
Celebrate Huntington’s Disease Awareness Month this May
May is officially Huntington's Disease Awareness Month! Read all about the proclamation in this post: https://huntingtonstudygroup.org/hd-insights/vol27_hdawarenessmonth/
Thanks to UCI MIND for highlighting our 10 years of hard work!
In the UCI MIND quarterly newsletter, HD-CARE is celebrated as 10 years as a non-profit organization! Check out the article along with other exciting news from UCI: https://mind.uci.edu/mind-matters-quarterly-newsletter-winter-2023/
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease
From Huntington Study Group: Prilenia Therapeutics B.V., a clinical stage biotechnology company, met a milestone that the last participant in PROOF-HD, a global Phase 3 study in Huntington’s disease (HD),…